Source comparison
CJC-1295 No DAC & Ipamorelin Research: Protocol Comparison
Sampling Intervals Baseline + 30 min sufficient Baseline + 45 min sufficient Baseline + 15 min + 60 min + 120 min required Combined protocols require interval sampling to capture synergistic secondary peak. Single-timepoint methods miss 40% of secretory activi
This comparison does not assign a generated winner or score.
- Sampling Intervals
- Baseline + 30 min sufficient
- Baseline + 45 min sufficient
- Baseline + 15 min + 60 min + 120 min required
- Combined protocols require interval sampling to capture synergistic secondary peak. Single-timepoint methods miss 40% of secretory activity
- Storage Temperature
- −20°C lyophilized, 2–8°C reconstituted
- No difference in storage requirements, but combined vials must be tracked separately with individual reconstitution dates
- Expected GH Peak Magnitude
- 2–3× baseline at 30 min
- 3–4× baseline at 45 min
- 5–7× baseline at 60 min with sustained elevation at 120 min
- Synergistic effect produces higher peak and longer duration than either compound alone. This is the primary rationale for combination use
- Common Adverse Events
- Rare at research doses
- Flushing (15–25%), nausea (8–12%), appetite increase (40–50%)
- Same as ipamorelin plus transient dizziness (5–8%) at 90–120 min
- Adverse event profile is driven by ipamorelin's ghrelin receptor activation. CJC-1295 contributes minimal additional events
- Reconstitution Stability
- 28 days at 2–8°C
- 28 days at 2–8°C per peptide
- Both peptides stable for 28 days but degradation accelerates after day 21. Protocols >3 weeks require midpoint reconstitution
- Baseline Fasting Requirement
- 8–12 hours
- Fasting is mandatory for all GH secretagogue research to eliminate dietary glucose interference with GH measurement